News

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Ali Erginay, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Dr Yorston delivered the Gisbert Richard Lecture at this year's EURETINA Congress

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year.

David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.

Dilsher Dhoot, MD, sat down with Modern Retina to provide some insights on the phase 1 HELIOS trial, which he presented on during the 2024 ASRS meeting held in Stockholm, Sweden earlier in 2024.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile.

Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Lloyd Clark, MD, discusses the evolution and current practices in the treatment of common retinal diseases such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

At EyeCon 2024, Analisa Arosemena, MD, discussed the shift away from traditional topical therapies towards more proactive management techniques, aiming to enhance patient outcomes in glaucoma care.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space

A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.

Three resident eye care providers—Anupam Garg, MD, PhD; Khanh Huang, OD; and Shail Patel, MD—were honored with the Visionary in Eye Care award at EyeCon 2024, which recognizes their achievements and contributions during their residency programs.

Adam S. Wenick, MD, PhD, discussed myopia interventions across the lifespan at EyeCon 2024, covering treatments, complications, and prevention strategies.

David Chin Yee, MD, sat down with Ophthalmology Times to discuss his presentation on what every Optometrist and Ophthalmologist should know about geographic atrophy at Eyecon 2024.

Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on collaboration, featuring topics like red flags for patient care, thyroid eye disease, and diabetes management.

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.